Literature DB >> 22997459

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

H Tilly1, U Vitolo, J Walewski, M Gomes da Silva, O Shpilberg, M André, M Pfreundschuh, M Dreyling.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22997459     DOI： 10.1093/annonc/mds273

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  41 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.

Authors:  Silvia Morbelli; Selene Capitanio; Fabrizio De Carli; Francesca Bongioanni; Enrico De Astis; Maurizio Miglino; Maria Teresa Verardi; Ambra Buschiazzo; Francesco Fiz; Cecilia Marini; Elena Pomposelli; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-19       Impact factor: 9.236

Review 3.  FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Thomas C Kwee; Bart de Keizer; Rob Fijnheer; John M H de Klerk; Rutger A J Nievelstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-27       Impact factor: 9.236

4.  Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

Authors:  David M Kurtz; Michael R Green; Scott V Bratman; Florian Scherer; Chih Long Liu; Christian A Kunder; Kazuhiro Takahashi; Cynthia Glover; Colm Keane; Shingo Kihira; Brendan Visser; Jason Callahan; Katherine A Kong; Malek Faham; Karen S Corbelli; David Miklos; Ranjana H Advani; Ronald Levy; Rodney J Hicks; Mark Hertzberg; Robert S Ohgami; Maher K Gandhi; Maximilian Diehn; Ash A Alizadeh
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

5.  Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.

Authors:  M Joerger; C Schaer-Thuer; D Koeberle; K Matter-Walstra; J Gibbons-Marsico; S Diem; B Thuerlimann; T Cerny
Journal:  Eur J Clin Pharmacol       Date:  2014-03-11       Impact factor: 2.953

6.  Use of Model-Based Iterative Reconstruction (MBIR) in reduced-dose CT for routine follow-up of patients with malignant lymphoma: dose savings, image quality and phantom study.

Authors:  Edouard Hérin; François Gardavaud; Mélanie Chiaradia; Pauline Beaussart; Philippe Richard; Madeleine Cavet; Jean-François Deux; Corinne Haioun; Emmanuel Itti; Alain Rahmouni; Alain Luciani
Journal:  Eur Radiol       Date:  2015-03-08       Impact factor: 5.315

7.  Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.

Authors:  Antoinette de Jong; Thomas C Kwee; John M H de Klerk; Judit A Adam; Bart de Keizer; Rob Fijnheer; Marie José Kersten; Inge Ludwig; Yvonne W S Jauw; Josée M Zijlstra; Indra C Pieters-Van den Bos; Jaap Stoker; Otto S Hoekstra; Rutger A J Nievelstein
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-04-25

8.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

9.  Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.

Authors:  Wendy J Langeberg; Conchitina C Siozon; John H Page; P K Morrow; Victoria M Chia
Journal:  Support Care Cancer       Date:  2014-03-21       Impact factor: 3.603

Review 10.  FDG-PET imaging in hematological malignancies.

Authors:  L Valls; C Badve; S Avril; K Herrmann; P Faulhaber; J O'Donnell; N Avril
Journal:  Blood Rev       Date:  2016-04-16       Impact factor: 8.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.